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dependent repression. The authors also 
report that the Nurr1-CoREST interac-
tion is stimulated by phosphorylation of 
Nurr1 by Nemo-like kinase. Lastly, ChIP 
analysis of iNOS promoter occupancy 
following stimulation by LPS suggests 
a temporal model of transrepression in 
which p65 binding precedes Nurr1 asso-
ciation, which is followed by recruitment 
of  CoREST to the complex.
The Saijo et al. study provides impor-
tant insights into the ability of Nurr1 and 
 CoREST to modulate neuroinflammation. 
The work unravels molecular mechanisms 
that may underlie human neurological dis-
ease and opens the door for future work on 
inflammatory signaling in the brain. These 
studies also provide a better understand-
ing of how transrepression is achieved at 
the molecular level. Interestingly, certain 
components of the transrepression mech-
anism appear to be conserved between 
different nuclear receptors, such as the 
requirement for sumoylation and the inter-
action with NF-κB proteins and corepres-
sors. At the same time, Saijo et al. illustrate 
how different nuclear receptors utilize dis-
tinct corepressor complexes to repress 
gene expression in a signal- and context-
dependent manner.
Finally, the work prompts a number of 
interesting questions to be addressed 
in future studies. For example, the three 
NR4A receptors (Nurr77, Nurr1, and 
Nor1) regulate overlapping target genes 
in some cell types. Do Nurr77 and Nor1 
also interact with CoREST in response to 
inflammatory signals? What is the rela-
tive contribution of transrepression and 
direct gene activation in NR4A-depen-
dent regulation of inflammation? Sumoy-
lation appears to be a critical component 
of the transrepression mechanism. In the 
PPAR and LXR transrepression path-
ways, sumoylation of the receptor is trig-
gered by ligand binding. Is Nurr1 sumoy-
lation responsive to other cellular signals 
in addition to IL-1β? Is the Nurr1/CoREST 
transrepression pathway intact in mono-
cytes and macrophages, and if so, does 
this repression pathway also have a role 
in peripheral inflammation? Lastly, there 
is strong evidence that neuroinflamma-
tion contributes to the pathogenesis of a 
number of diseases, including Alzheim-
er’s disease and multiple sclerosis. It will 
be important to determine if this repres-
sion pathway is altered in these diseases 
and whether NR4A receptors might rep-
resent potential therapeutic targets.
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Although much is known about the genes that promote metastasis, few suppressors of metastasis 
have been found. Adorno et al. (2009) now identify p63 as a potent suppressor of metastasis and 
uncover an intricate mechanism for the inactivation of metastasis in cancer cells in response to 
transforming growth factor β.28 Cell 137, April 3, 2009 ©2009 Elsevier Inc.tumors where it promotes metastasis 
(Padua and Massague, 2009). Reporting 
in this issue of Cell, Adorno et al. (2009) 
identify a mechanism in cells express-
ing mutant p53, which enables TGFβ to 
switch to an oncogenic role by promot-
ing mutant p53-mediated suppression of cytokine transforming growth factor β 
(TGFβ) has emerged as a major player in 
the metastatic process, it has seemingly 
contradictory functions. Ordinarily a 
tumor suppressor that mediates growth 
arrest and apoptosis, TGFβ appears to 
take on the opposite role in end-stage Cancer progression from the primary 
phase to the metastatic phase rep-
resents one of the key determinants 
of prognosis and outcome for cancer 
patients. However, the mechanistic 
details behind the metastatic spread of 
cancer remain obscure. Although the 
they unexpectedly find that in response 
to TGFβ, mutant p53 induces a dramatic 
alteration in cell morphology that is indic-
ative of increased migration capacity. 
Further analysis by the authors reveals 
that mutant p53 is responsible for the 
ability of cultured human breast cancer 
cells to migrate, invade, and metasta-
size in both in vitro and in vivo assays. 
Building on previous observations that 
mice lacking one copy of the p53 gene 
and one copy of either the p63 or p73 the related p63 protein, thus uncovering 
a new role for p63 in the negative regula-
tion of metastasis.
The starting point in uncovering this 
mechanism was a simple experiment to 
determine whether the cellular response 
to TGFβ differed between cells express-
ing wild-type and mutant p53. Adorno et 
al. confirm that wild-type p53 plays an 
important role in the tumor-suppressive 
function of TGFβ by promoting growth 
arrest and upregulation of p21. However, Cegene developed tumors with metastatic 
potential (Flores et al., 2005), Adorno 
and colleagues show that inactivation of 
p63 promotes the oncogenic function of 
TGFβ. In contrast, overexpression of p63 
strongly inhibits the metastatic potential 
conferred by mutant p53, indicating that 
the antimetastatic function of p63 lies 
downstream of mutant p53.
Adorno et al. find that Smad proteins 
act as an essential scaffold for mutant 
p53 to sequester p63, possibly disrupt-
ing the function of p63 as a transcrip-
tional activator. The formation of a ter-
nary mutant p53/Smad/p63 complex 
is exquisitely dependent upon the level 
of TGFβ signaling. As the level of TGFβ 
increases, mutant p53 titrates away 
increasing amounts of free p63, thereby 
possibly preventing p63 from binding to 
the promoters of its transcriptional tar-
gets. Intriguingly, in addition to requiring 
TGFβ signaling, the formation of a ternary 
mutant p53/Smad/p63 complex also 
requires oncogenic Ras (RasV12) signal-
ing in a manner similar to Ras activation 
of wild-type p53 (Cordenonsi et al., 2007) 
(Figure 1). Though this mechanism of p63 
regulation in the context of mutant p53 is 
compelling, it should be noted that the 
role of the p63/Smad complex in normal 
cells remains to be established. Indirect 
evidence suggests that wild-type p53 
does not affect the antimetastatic func-
tion of p63, but the question remains 
figure 1. TGfβ and Ras/MAPK crosstalk in 
cancer and Metastasis
(Top) In normal cells with wild-type p53, aberrant 
Ras/mitogen-activated protein kinase (MAPK) sig-
naling downstream of receptor tyrosine kinases (for 
example, driven by the constitutively active mutant 
Ras protein RasV12) promotes the phosphoryla-
tion of p53 by the kinase CK1δ/ε. Phosphorylated 
p53 can cooperate with TGFβ signaling to induce 
growth arrest and to inhibit tumor formation. Simi-
larly, p63, perhaps in combination with activated 
Smad proteins, also has tumor-suppressive func-
tions and can suppress metastasis.
(Middle) In cells lacking p53 (p53 null), aberrant 
Ras/MAPK signaling can drive proliferation and 
initiate tumorigenesis. However, as p63 is still 
present, the metastasis of the primary tumor is 
blocked. It remains to be confirmed whether TGFβ 
signaling is required to enhance the antimetastatic 
effects of p63.
(Bottom) In cells expressing mutant p53, normal 
p53 function is disrupted, allowing for tumor ini-
tiation. The mutant protein can also sequester 
p63 in response to TGFβ signaling, thereby ab-
rogating p63 function and promoting metastatic 
progression.ll 137, April 3, 2009 ©2009 Elsevier Inc. 29
whether a wild-type p53/Smad/p63 
complex dependent on Ras and TGFβ 
signaling also exists. This complex could 
function in tumor suppression in normal 
cells as well as play a role in regulating 
tumor cells in the presence of aberrant 
Ras activation (Figure 1).
To better understand how p63 inacti-
vation promotes metastasis, Adorno et 
al. identify essential targets of mutant 
p53 and TGFβ that could be responsible 
for the metastatic potential. Their analy-
sis reveals a restricted set of five genes 
that are coregulated by both mutant p53 
and TGFβ. Of these, the genes encod-
ing Sharp-1 (BHLHE41) and cyclin G2 
(CCGN2) are p63 targets whose expres-
sion is impaired upon p63 inactivation. 
Inactivation of either gene restores 
TGFβ-dependent promigratory activities 
in cultured p53-deficient breast tumor 
cells, suggesting that their gene prod-
ucts mediate the antimetastatic func-
tions of p63. It remains to be determined 
how Sharp-1 and cyclin G2 act to inhibit 
the metastatic process. Cyclin G2 is 
known to be upregulated in response to 
DNA damage and can promote cell-cycle 
arrest (Arachchige Don et al., 2006), a 
function typical of a tumor suppressor. 
However, a direct role in metastasis for 
Sharp-1, a regulator of circadian oscilla-
tion and feedback (Rossner et al., 2008), 
is not immediately apparent. Provoca-
tively, although neither of these genes 
has been previously identified in known 
gene expression signatures for breast 
cancer metastasis (Fan et al., 2006), 
their prognostic value holds in analyses 
of datasets from 1200 primary breast 
cancers and associated clinical data. 
The authors categorize patients in those 
datasets into two groups that have either 
high or low expression of Sharp-1 or 
cyclin G2. Survival analysis indicates that 
“low-expression” groups have a mark-
edly higher probability of cancer recur-
rence than “high-expression” groups. 
Remarkably, this simple stratification of 
patients based on a two gene “minimal 
signature” was comparable to the strati-
fication based on a 70 gene breast can-
cer metastasis expression profile (Fan et 
al., 2006).
Taken together, these new findings are 
of tremendous value. Although the pub-
lished literature points to a large number 
of possible metastasis enhancers, our 30 Cell 137, April 3, 2009 ©2009 Elsevier Inccurrent knowledge on specific metas-
tasis suppressors is sparse. Hence, the 
identification of p63 is a seminal find-
ing that could launch a race to identify 
additional suppressors of metastasis. 
Adorno et al. clearly demonstrate that 
loss of p63 function is critical to TGFβ-
mediated metastatic potential. However, 
their findings do not fully address why 
cancer cells would develop such an intri-
cate mechanism to inactivate the protein 
rather than simply mutating or losing the 
gene during tumor progression. Clues 
to why cells maintain the p63 gene may 
come from its role as a key determinant 
of epithelial stem cell proliferative poten-
tial (Senoo et al., 2007). Indeed, an abil-
ity to modulate p63 activity in a quantita-
tive manner according to TGFβ signaling 
would allow regulation of epithelial cell 
fate within the developing tumor. A high 
level of TGFβ signaling within the primary 
tumor would promote p63 inactivation to 
allow for acquisition of metastatic poten-
tial. However, after migration of primary 
tumor cells to distant metastatic sites, 
decreased TGFβ signals at those sites 
would allow for reactivation of p63 func-
tion, thereby enabling efficient propa-
gation of cells to form the secondary 
tumor.
Another important implication of 
Adorno et al.’s study is the proposition 
of a minimal metastatic signature involv-
ing the expression of genes encoding 
Sharp-1 and cyclin G2. The fact that 
expression of these two genes alone can 
efficiently stratify cancer patients and 
predict the metastatic potential of their 
tumors represents a tremendous advance 
over the more elaborate metastatic sig-
natures that have been proposed to date 
(Fan et al., 2006). Although a TGFβ sig-
nature in a subset of breast tumors can 
predict metastatic spreading to the lung 
(Padua et al., 2008), Sharp-1 and cyclin 
G2 may represent a more effective “min-
imal signature.” This is because they 
are identified through the comparative 
analysis of microarray datasets selected 
on the basis of mechanistic insights (for 
example, the gene expression signature 
of cells in the presence or absence of 
TGFβ compared to that of cells harbor-
ing wild-type or mutant p53) rather than 
on the basis of metastatic outcome and 
tumor type. However, feedback from the 
cancer community will be important to .understand if such a minimal signature 
holds not only for breast cancers but 
also for epithelial cancers derived from 
other organs.
Finally, from a therapeutic perspective, 
it will be interesting to understand how to 
take advantage of the mechanistic details 
unveiled by Adorno et al. To date, the idea 
of anti-TGFβ cancer therapies has been 
met with caution due to the dual nature of 
the TGFβ signaling pathway in promoting 
both tumor suppression and metastasis. 
However, the targeting of the mutant p53/
Smad/p63 complex now represents one 
potential option for therapeutic interven-
tion. Small molecules that disrupt the 
binding of mutant p53 to Smad/p63 may 
promote p63 release from the complex 
to inhibit metastasis. Similarly, inhibitors 
of CK1δ/ε, the kinase proposed to phos-
phorylate p53 downstream of receptor 
tyrosine kinase/Ras signaling, could also 
disrupt the p53/Smad/p63 complex and 
are already in clinical trials. Thus, beyond 
shedding light on the metastatic process, 
the work of Adorno et al. underscores the 
potential clinical value in identifying and 
characterizing metastatic suppressors 
through mechanistic study.
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